Ahmad Al-Huniti

Ahmad Al-Huniti

Auto-generated profile, based on publicly available information

Ahmad Al-Huniti

Division of Pediatric Hematology/Oncology and Robert D. and Patricia E. Kern Center for the Science of Health Care Delivery, Mayo Clinic, Rochester, Minnesota, USA

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 April 2020 in Haemophilia
Verified
Journal Article
Closed access
PDF file
AAAhmad Al‐Huniti
Ahmad Al‐Huniti
MHMelanie Reyes Hernandez
Melanie Reyes Hernandez
PEPatrick Ten Eyck
Patrick Ten Eyck
JSJanice M. Staber
Janice M. Staber

14 May 2025 in Journal of Thrombosis and Haemostasis
Verified
Journal Article
Open access
AAAhmad H. Al-Huniti
Ahmad H. Al-Huniti
CMCaroline Malcolmson
Caroline Malcolmson
VLValerie Langlois
Valerie Langlois
AMAshlene M. McKay
Ashlene M. McKay
ALArmando Lorenzo
Armando Lorenzo
LBLeonardo R. Brandão
Leonardo R. Brandão
Graft thrombosis is a preventable cause of early allograft loss after pediatric kidney transplant, but the role of primary thromboprophylaxis is uncertain. To determine the effectiveness and safety of thromboprophylaxis in preventing graft thrombosis among children (0-21 years) undergoing kidney transplant. We performed a systematic literature review of MEDLINE, Embase, and Cochrane Libraries from inception until September 2024. The primary outcome assessed by meta-analysis was graft thrombosis, and the secondary outcome was major bleeding (per International Society on Thrombosis and Haemostasis criteria). Twenty-five observational studies (21 retrospective, 4 prospective) describing 2,094 patients (1,659 cases, 435 controls) met eligibility criteria. Thromboprophylaxis was used universally (ie, all kidney recipients in the study) in 64% (1,055/1,659) or only in high-risk patients (recipient weight <20 kg, age <5 years) in 36% (604/1,659). Compared with no preventive measures for thrombosis, thromboprophylaxis was associated with reduced risk of graft thrombosis (odds ratio, 0.31; 95% CI, 0.18-0.53). Subgroup analyses of heparinoid-only, universal thromboprophylaxis, and high-risk-only protocols revealed similar findings. Thromboprophylaxis was not associated with increased risk of bleeding resulting in surgical exploration or graft loss. The overall risk of bias was moderate. Studies showed high clinical and methodologic heterogeneity in study populations and thromboprophylaxis protocols. Primary thromboprophylaxis appears effective in preventing kidney graft loss from vascular thrombosis in pediatric recipients. This benefit may be offset by the risk of bleeding, although clarity on bleeding risk factors is lacking. We identified knowledge gaps, including uncertainty about optimal thromboprophylaxis regimens and treatment duration.

26 July 2024 in Blood Vessels, Thrombosis & Hemostasis
Verified
Journal Article
Open access
SVSilvia Verhofste
Silvia Verhofste
AAAhmad Al-Huniti
Ahmad Al-Huniti
MNMarci Novak
Marci Novak
ACAmy L Conrad
Amy L Conrad
Ellen Van Der PlasEllen Van Der Plas
Ellen Van Der Plas
JSJanice M. Staber
Janice M. Staber
• Cerebellar gray matter volume in our HA cohort is disproportionately smaller than in healthy controls. • Smaller cerebellar gray matter volume was associated with measures of executive dysfunction in HA.

20 March 2024 in Haemophilia
Verified
Journal Article
Closed access
PDF file
AAAhmad Al‐Huniti
Ahmad Al‐Huniti
LMLinda Marshall
Linda Marshall
DRDawn Rusk
Dawn Rusk
RPRajiv K. Pruthi
Rajiv K. Pruthi
VRVilmarie Rodriguez
Vilmarie Rodriguez
AKAlexis Kuhn
Alexis Kuhn

24 November 2021 in Journal of Vascular Anomalies
Verified
Journal Article
Open access
AAAhmad Al-Huniti
Ahmad Al-Huniti
MFMichelle Fantauzzi
Michelle Fantauzzi
LWLaura Willis
Laura Willis
MSMuriel Sadlier
Muriel Sadlier
JAJoao G. Amaral
Joao G. Amaral
MCManuel D. Carcao
Manuel D. Carcao
Purpose: Fibroadipose vascular anomaly (FAVA) is a complex vascular anomaly associated with postzygotic somatic PIK3CA mutations. FAVAs can cause significant pain, swelling, and musculoskeletal dysfunction. Treatment options are limited. Sirolimus is a well-tolerated and effective treatment for patients with FAVA. We report our experience of using sirolimus to treat 11 children with FAVAs. Methods: We conducted a retrospective review of all patients with FAVA treated with sirolimus in our institution. Results: Fourteen patients (10 females) were referred for sirolimus therapy for FAVA. Eleven patients were initiated on sirolimus at a mean age of 14 years (range: 9–17.9 years) and were then treated for a mean of 19 months (range: 1–46 months). Five had previously undergone sclerotherapy without benefit. Sirolimus was initiated at a dose of either 2.5 mg/m2 once daily or 0.8 mg/m2 twice daily. Doses were titrated to maintain sirolimus trough levels of 5–15 ng/L. Goals of treatment were improvement in pain and musculoskeletal dysfunction. All 11 patients reported reduced pain; 7 reporting this within 3 weeks of starting sirolimus. This allowed for discontinuation of analgesia. Function improved significantly in 9 of 11, leading to resumption of sports or work participation. Sirolimus side effects were similar to prior reports, most commonly mouth sores, mildly elevated lipids and acne. There was no grade III/IV toxicity. Conclusion: Sirolimus is a well-tolerated and effective treatment for patients with FAVA. Initial symptom improvement is rapid, with significantly reduced pain and improved function. We believe that sirolimus should be considered for all patients with FAVA as a first-line therapy before surgical/interventional approaches.